Vessel co-option in cancer
All solid tumours require a vascular supply in order to progress. Although the ability to
induce angiogenesis (new blood vessel growth) has long been regarded as essential to this …
induce angiogenesis (new blood vessel growth) has long been regarded as essential to this …
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
RR Ramjiawan, AW Griffioen, DG Duda - Angiogenesis, 2017 - Springer
Angiogenesis is defined as the formation of new blood vessels from preexisting vessels and
has been characterized as an essential process for tumor cell proliferation and viability. This …
has been characterized as an essential process for tumor cell proliferation and viability. This …
Systemic therapy for melanoma: ASCO guideline
R Seth, H Messersmith, V Kaur, JM Kirkwood… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To provide guidance to clinicians regarding the use of systemic therapy for
melanoma. METHODS ASCO convened an Expert Panel and conducted a systematic …
melanoma. METHODS ASCO convened an Expert Panel and conducted a systematic …
Systemic therapy for melanoma: ASCO guideline update
R Seth, SS Agarwala, H Messersmith… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To provide guidance to clinicians regarding the use of systemic therapy for
melanoma. METHODS American Society of Clinical Oncology convened an Expert Panel …
melanoma. METHODS American Society of Clinical Oncology convened an Expert Panel …
Antiangiogenic therapy in oncology: current status and future directions
Angiogenesis, the formation of new blood vessels from pre-existing vessels, has been
validated as a target in several tumour types through randomised trials, incorporating …
validated as a target in several tumour types through randomised trials, incorporating …
Melanoma
D Schadendorf, DE Fisher, C Garbe… - Nature reviews Disease …, 2015 - nature.com
Melanoma is a common cancer in the Western world with an increasing incidence. Sun
exposure is still considered to be the major risk factor for melanoma. The prognosis of …
exposure is still considered to be the major risk factor for melanoma. The prognosis of …
The treatment of advanced melanoma: therapeutic update
A Villani, L Potestio, G Fabbrocini, G Troncone… - International journal of …, 2022 - mdpi.com
Cutaneous melanoma is the main cause of death for skin cancer. The majority of patients
with a diagnosis of melanoma have localized disease, which can be successfully treated …
with a diagnosis of melanoma have localized disease, which can be successfully treated …
ctDNA monitoring using patient-specific sequencing and integration of variant reads
Circulating tumor-derived DNA (ctDNA) can be used to monitor cancer dynamics
noninvasively. Detection of ctDNA can be challenging in patients with low-volume or …
noninvasively. Detection of ctDNA can be challenging in patients with low-volume or …
Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis
Background The cardiovascular risk of angiogenesis inhibitors is not well-quantified. We
hypothesized that, compared to direct vascular endothelial growth factor (VEGF) inhibitors …
hypothesized that, compared to direct vascular endothelial growth factor (VEGF) inhibitors …
Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma
GT Gibney, RR Kudchadkar, RC DeConti… - Clinical Cancer …, 2015 - AACR
Purpose: The anti-programmed death-1 (PD-1) antibody nivolumab (BMS-936558) has
clinical activity in patients with metastatic melanoma. Nivolumab plus vaccine was …
clinical activity in patients with metastatic melanoma. Nivolumab plus vaccine was …